884490-86-2

Upstream product

• 431989-55-8 methyl 5-{3-[(2R)-2-(hydroxymethyl)-5-oxo-1-pyrrolidinyl]propyl}-2-thiophenecarboxylate 
• 107-06-2 1,2-dichloro-ethane 
• 431989-54-7 (R)-methyl 5-(3-(2-formyl-5-oxopyrrolidin-1-yl)propyl)thiophene-2-carboxylate 
• 73718-79-3 [2-oxo-3-(3-trifluoromethyl-phenyl)-propyl]-phosphonic acid dimethyl ester 
• 431990-32-8 5-{3-[2-(tert-butyl-dimethyl-silanyloxymethyl)-5-oxo-pyrrolidin-1-yl]-prop-1-ynyl}-thiophene-2-carboxylic acid methyl ester 
• 431990-31-7 (R)-5-(t-butyldimethylsiloxymethyl)-1-(2-propynyl)-2-pyrrolidinone 
• 62224-19-5 5-bromo-2-thiophenecarboxylic acid methyl ester 
• 128899-30-9 (R)-5-(((tert-butyldimethylsilyl)oxy)methyl)pyrrolidin-2-one 

Downstream Products

• 431990-11-3 5-(3-{(2S)-[(3R)-3-hydroxy-4-(3-trifluoromethyl-phenyl)-butyl]-5-oxo-pyrrolidin-1-yl}-propyl)-thiophene-2-carboxylic acid methyl ester 

Relevant academic research and scientific papers

Discovery of highly selective EP4 receptor agonists that stimulate new bone formation and restore bone mass in ovariectomized rats

Heptanoic acid lactams, exemplified by 2, were identified as highly selective EP4 agonists via high throughput screening. Lead optimization led to the identification of lactams with a 30-fold increase in EP4 potency in vitro. Compounds demonstrated robust

CONTINUOUS COMBINATION THERAPY WITH SELECTIVE PROSTAGLANDIN EP4, RECEPTOR AGONISTS AND AN ESTROGEN FOR THE TREATMENT OF CONDITIONS THAT PRESENT WITH LOW BONE MASS

This invention is directed to methods for treating conditions which present with low bone mass in a patient in need thereof using continuous combination therapy with a synergistically effective combination of an EP4 receptor selective agonist o